ESG

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A landmark private equity deal in Europe's produce sector is about more than money; it's a strategic move to build a resilient food supply chain.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

With backing from the US and Australia, a titanium giant is pivoting to critical minerals, a strategic move challenging global supply chain dominance.

A leading stainless steel giant partners with a spiritual organization to tackle addiction, signaling a strategic shift in corporate social responsibility.

Insiders at the newly independent Magnum Ice Cream Company show major confidence with multi-million-euro share buys following its spin-off from Unilever.

NUS scientists unveil a microneedle patch for plants, slashing waste and boosting growth. A new investment frontier in high-end, sustainable agriculture.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?

Amid rapid expansion and heightened regulatory scrutiny, PACS Group hires new compliance and HR chiefs to fortify its operational foundation for the future.

As Thailand braces for another toxic smog season, air purifier giant Levoit deploys a timely strategy to capture a market born from a public health crisis.

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.